Venstra Medical develops a percutaneous ventricular assist device pVAD that delivers 7 liters per minute at 60 mmHg through a 9F delivery system, providing temporary cardiac support during critical procedures. This technology addresses the high mortality risk associated with cardiogenic shock and supports patients undergoing percutaneous coronary interventions.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiogenic shock and high-risk percutaneous coronary interventions (PCI) present significant mortality risks for cardiac patients due to dangerously low cardiac output or the need for circulatory support during procedures. Existing solutions may be too invasive or lack sufficient pumping capacity.
Solution
Venstra Medical is developing a next-generation percutaneous ventricular assist device (pVAD) designed to provide temporary cardiac support. The device is delivered through a 9F delivery system and is capable of pumping 7 liters per minute at 60 mmHg. This pVAD aims to improve outcomes for patients experiencing cardiogenic shock or undergoing high-risk PCI by providing effective circulatory assistance with a less invasive approach.
Target Audience
The primary target audience includes cardiologists and hospitals treating patients experiencing cardiogenic shock or undergoing high-risk percutaneous coronary interventions (PCI).
Features
- Percutaneous ventricular assist device (pVAD) for temporary cardiac support
- 7 liters per minute pumping capacity at 60 mmHg pressure
- 9F delivery system for less invasive implantation
- Designed for use in cardiogenic shock and high-risk PCI procedures